Excelra is a global data and analytics company serving the Life Sciences sector, with deep expertise across drug discovery informatics, real-world evidence (RWE), and data-driven research solutions. Headquartered in the United States and India, the company supports pharmaceutical and biotech clients worldwide through proprietary datasets, domain-led analytics, and technology-enabled scientific platforms.

Novistra Capital served as the exclusive buy-side advisor to Excelra on its majority investment in Anilitiks, a specialist provider of HEOR and real-world evidence analytics. Our team led a highly targeted process focused on identifying a platform with complementary scientific depth, strong delivery capability, and global pharma exposure. We supported Excelra across all phases of the acquisition — strategic fit assessment, valuation analysis, diligence, and final execution — ensuring alignment on capabilities, culture, and long-term integration strategy.

The investment expands Excelra’s data-driven Life Sciences solutions portfolio, adding advanced HEOR, market access, and RWE analytics capabilities tailored to global pharmaceutical clients. The combined expertise strengthens Excelra’s position as a leading provider of scientific data and evidence-generation solutions, enabling deeper engagement across the drug development and commercialisation lifecycle.